
Impact of House passed legislation on health industries organizations
Summary of the impact of House passed legislation on the pharmaceutical, life sciences, medtech and health services sectors including PwC key observations.
The Trump administration’s implementation of “reciprocal tariffs” continues to be dynamic, prompting a challenging trade landscape for many multinational companies. The President signed an executive order on April 2, made announcements, and released memoranda on this matter. In summary, the new tariffs in place as of the date of this Insight include the following (this list does not reflect all previously existing tariffs):
A wider industry perspective can be found in PwC’s US Tariff Industry Analysis Insight published on April 22 and additional information can be found in the US Customs and Border Protection CBP tariff requirements released May 2. The administration recently noted that more than 100 countries wish to negotiate trade imbalances with a drive towards an economic level playing field and fair-trading system. As of the date of this Insight, no change in previously noted rates has been announced.
Tariffs introduce new complexities for private equity (PE) firms amid rising recession risks driven by softening consumer demand and growing macroeconomic uncertainty. Trade-driven inflation, combined with ongoing monetary tightening, may elevate the cost of capital, affecting leveraged transactions and refinancing conditions. Capital could shift toward domestic or less trade-exposed sectors like enterprise software and business services. Firms also should anticipate heightened demand for restructuring and turnaround opportunities as some portfolio companies struggle with unexpected tariff impacts.
Reciprocal and current tariffs are affecting private equity firms across both the pre-deal and post-deal periods. Prior to the deal, firms face heightened market volatility, reduced cross-border deal flow, and increased due diligence requirements related to trade exposure and supply chain risks in target companies. Following the deal, tariffs are driving increased portfolio company costs, supply chain disruptions, and potential margin pressure—particularly for investments in trade-exposed sectors such as manufacturing, healthcare, and industrials.
This Tax Insight serves as an update to our March 17 Industry Analysis, which previously included forecasted reciprocal tariff rates at that time. Note: PwC’s updated Industry Analysis utilizes the tariffs that have been implemented by the United States as of April 15 (based on the guidance and specific factors explained in the next section) as well as potential tariffs on so-called Annex II products.
To mitigate the impact of the reciprocal and current tariffs, PE firms can support their portfolio companies by considering diversifying supply chains, reassessing sourcing locations, leveraging tariff engineering, and implementing dynamic pricing models to manage rising costs and maintain competitiveness. Firms also should explore trade programs—such as free trade agreements (FTAs), duty drawback, and foreign-trade zones—to mitigate or defer tariff-related expenses. Additionally, firms may need to assess how evolving trade policies affect cross-border deal flow and consider shifting investments strategies toward sectors and geographies less exposed to tariff risk, including opportunities in domestic markets. Coordination efforts across procurement, supply chain, tax, and leadership teams are critical to develop cohesive short, medium, and long-term responses. Leveraging advanced data tools—particularly US customs data—can help quantify the true financial impact and uncover “no-regret” actions that support strategic decision-making and risk mitigation.
For more details, read the full Tax Insight linked below.
Summary of the impact of House passed legislation on the pharmaceutical, life sciences, medtech and health services sectors including PwC key observations.
The House-passed HR 1 proposes major changes for financial services, including limits on PTE tax, a higher SALT cap, and increasing US tax for certain inbound investors.
House-passed “One Big Beautiful Bill” includes significant information reporting provisions
Washington legislation includes significant tax changes including for B&O tax, sales and use tax, and capital gains tax.